FDA reviewing Sun's psoriasis candidate

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA accepted a BLA for tildrakizumab (MK-3222) to treat moderate to severe plaque psoriasis. The company declined to disclose the candidate's PDUFA date.

Sun has worldwide, ex-European rights to tildrakizumab from Merck & Co. Inc. (NYSE:MRK). In March, EMA validated an MAA for the mAb against IL-23...